重药控股：2025年半年度报告

Core Insights - The company reported a revenue of 41,188,217,331.84 yuan for the first half of 2025, reflecting a year-on-year growth of 3.54% [1] - The net profit attributable to shareholders reached 282,265,967.39 yuan, marking an 18.56% increase compared to the previous year [1] Financial Performance - Revenue for H1 2025: 41.19 billion yuan, up 3.54% year-on-year [1] - Net profit for H1 2025: 282.27 million yuan, up 18.56% year-on-year [1]